Molnupiravir has received emergency use authorization from DCGI for the treatment of adult patients with COVID-19 who are at high risk of disease progression, including hospitalization.
New Delhi: Drugmaker Lupine announced Friday that it has launched an antiviral drug Molnupiravir under the brand name Molnulup in the country for the treatment of COVID-19.
Molnupiravir has received emergency use authorization from the Drug Controller General of India (DCGI) for the treatment of adult patients with COVID-19 who are at high risk of disease progression, including hospitalization.
“Molnulup’s approval is timely as India is once again experiencing an increase in the incidences of COVID-19. In the past two years since the emergence of COVID-19, there is a need for an oral antiviral drug that can be prescribed by healthcare professionals. and then taken by patients conveniently at home, ”Lupine – India Region Formulations (IRF) President – Rajeev Sibal said in a statement.
Thanks to the company’s strong distribution network, Molnulup would be readily available in Indian pharmacies to meet patient demand, he added.
Internationally, molnupiravir is an oral antiviral drug that has been approved by the UK Medicines and Health Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) for the treatment of mild to moderate cases of COVID-19 in adults.
When administered orally, molnupiravir inhibits the replication of SARS-CoV-2, the causative agent of COVID-19.
Preclinical and clinical data have shown that Molnupiravir is effective against the most common variants of SARS-CoV-2, including the Gamma, Delta, and Mu variants.